{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:29:42Z","timestamp":1793608182085,"version":"4.5.0"},"reference-count":155,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.berh.2026.102162","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T19:57:15Z","timestamp":1779825435000},"page":"102162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous manifestations in myositis syndromes"],"prefix":"10.1016","volume":"40","author":[{"given":"Nathan C.","family":"Schedler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Raheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus Alberto Cardenas","family":"de la Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8949-1851","authenticated-orcid":false,"given":"John R.","family":"Edminister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2026.102162_bib1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(25)00233-9","article-title":"Advances in the classification and management of idiopathic inflammatory myopathies","volume":"24","author":"Raaphorst","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.berh.2026.102162_bib2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/cup.12504","article-title":"Specificity of dermal mucin in the diagnosis of lupus erythematosus: comparison with other dermatitides and normal skin","volume":"42","author":"Vincent","year":"2015","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.berh.2026.102162_bib3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaad.2017.12.074","article-title":"Dermatomyositis: a diagnostic dilemma","volume":"79","author":"Da Silva","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/bjd\/ljae247","article-title":"Social, disease and diagnostic factors associated with diagnostic delays in dermatomyositis: a retrospective cohort study","volume":"191","author":"Wanberg","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0560.2010.01516.x","article-title":"Marked papillary dermal edema \u2013 an unreliable discriminator between polymorphous light eruption and lupus erythematosus or dermatomyositis","volume":"37","author":"Pincus","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.berh.2026.102162_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/cup.13104","article-title":"Dermatomyositis: histopathologic findings of parakeratosis and dermal edema revisited","volume":"45","author":"Levy","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.berh.2026.102162_bib7","unstructured":"Bao A, Mecoli CA, Kelly W, et al. A single center retrospective analysis of inflammatory dermatologic diagnoses and misdiagnoses associated with dermatomyositis n.d."},{"key":"10.1016\/j.berh.2026.102162_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaneurol.2020.0673","article-title":"Association of dermatomyositis sine dermatitis with anti\u2013nuclear matrix protein 2 autoantibodies","volume":"77","author":"Inoue","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.berh.2026.102162_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jaad.2024.07.1530","article-title":"Overlapping clinical features in anti-synthetase syndrome and dermatomyositis: a case series","volume":"92","author":"Stone","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib10","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102162_bib11","article-title":"Validation of methods to identify people with idiopathic inflammatory myopathies using hospital episode statistics","volume":"6","author":"Hannah","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.berh.2026.102162_bib12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.abd.2021.02.008","article-title":"Skin manifestations associated with systemic diseases \u2013 part I","volume":"96","author":"Sampaio","year":"2021","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5826\/dpc.0701a15","article-title":"Acute onset of a severe rash on the face and dorsal hands","volume":"7","author":"Feily","year":"2017","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.berh.2026.102162_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.220089","article-title":"Cutaneous involvement in systemic lupus erythematous: a review for the rheumatologist","volume":"50","author":"Stull","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.17161\/kjm.vol1415224","article-title":"Concurrent dermatomyositis, celiac disease, and dermatitis herpetiformis in a patient with a history of morphea","volume":"14","author":"Jibbe","year":"2021","journal-title":"Kans J Med"},{"key":"10.1016\/j.berh.2026.102162_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jdcr.2024.05.015","article-title":"Anti-NXP2 antibody positive dermatomyositis presenting as unilateral heliotrope rash","volume":"50","author":"Saleh","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.berh.2026.102162_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/IOP.0000000000001258","article-title":"Unilateral eyelid swelling as a sign of antimelanoma differentiation\u2013associated gene 5 (Anti-MDA5)-Antibody\u2013Positive dermatomyositis","volume":"34","author":"Lam","year":"2018","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.berh.2026.102162_bib19","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1365-4362.2003.01696.x","article-title":"Periorbital edema as the presenting sign of dermatomyositis","volume":"42","author":"Hall","year":"2003","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib20","article-title":"Amyopathic dermatomyositis manifesting with marked unilateral eyelid swelling and hyperpigmentation in a darker skin tone","volume":"2","author":"Goupil","year":"2023","journal-title":"Ann Intern Med Clin Cases"},{"key":"10.1016\/j.berh.2026.102162_bib21","article-title":"Unilateral heliotrope rash in juvenile dermatomyositis: an unusual presentation of an underlying serious disease","volume":"2014","author":"Al-Janobi","year":"2014","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib22","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.40721","article-title":"Chronic erythematous swelling of unilateral eyelid: a quiz","volume":"104","author":"Chen","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.berh.2026.102162_bib23","first-page":"60","article-title":"Case report: clinically amyopathic dermatomyositis presenting acutely with isolated facial edema","volume":"7","author":"Pappa","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.berh.2026.102162_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000521362","article-title":"On the nose: anti-MDA-5 dermatomyositis manifesting as perinasal swelling","volume":"14","author":"Molina","year":"2022","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jdcr.2024.12.018","article-title":"Pseudoangioedema as a presenting symptom of dermatomyositis with antinuclear matrix protein 2 autoantibodies","volume":"58","author":"Li","year":"2025","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.berh.2026.102162_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1400575","article-title":"Case report: \u201cfur stole and turtleneck\u201d and \u201chalter-back\u201d signs: an expanded wardrobe for dermatomyositis","volume":"15","author":"Ho","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102162_bib27","doi-asserted-by":"crossref","DOI":"10.11604\/pamj.2014.18.150.4637","article-title":"Nail changes in connective tissue diseases : a study of 39 cases","volume":"18","author":"Elmansour","year":"2014","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.berh.2026.102162_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13185550","article-title":"Nailfold capillaroscopy changes in patients with idiopathic inflammatory myopathies","volume":"13","author":"Bogojevic","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.berh.2026.102162_bib29","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1007\/s10067-019-04710-2","article-title":"Nailfold videocapillaroscopy alterations in dermatomyositis, antisynthetase syndrome, overlap myositis, and immune-mediated necrotizing myopathy","volume":"38","author":"Soubrier","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.708432","article-title":"Nailfold capillaroscopy abnormalities correlate with disease activity in adult dermatomyositis","volume":"8","author":"Johnson","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.berh.2026.102162_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000464469","article-title":"Clinical and dermoscopic features of the scalp in 31 patients with dermatomyositis","volume":"3","author":"Jasso-Olivares","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.berh.2026.102162_bib32","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.1994.03520240067043","article-title":"Scalp involvement in dermatomyositis: often overlooked or misdiagnosed","volume":"272","author":"Kasteler","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2026.102162_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjd.14678","article-title":"Small\u2010fibre neuropathy in a patient with dermatomyositis and severe scalp pruritus","volume":"176","author":"Hurliman","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1159\/000520297","article-title":"Trichoscopic signs in dermatomyositis, systemic lupus erythematosus, and systemic sclerosis: a comparative study of 150 patients","volume":"238","author":"Chanprapaph","year":"2022","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.berh.2026.102162_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","article-title":"Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life","volume":"54","author":"Hundley","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","volume":"179","author":"Kim","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib37","first-page":"995","article-title":"Characterizing pruritus in autoimmune connective tissue diseases","volume":"18","author":"Yahya","year":"2019","journal-title":"J Drugs Dermatol JDD"},{"key":"10.1016\/j.berh.2026.102162_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13256-018-1618-y","article-title":"Erythroderma and extensive poikiloderma \u2013 a rare initial presentation of dermatomyositis: a case report","volume":"12","author":"Herath","year":"2018","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.berh.2026.102162_bib39","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","article-title":"Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood","volume":"371","author":"Feldman","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2026.102162_bib40","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/vaccines11050898","article-title":"Calcinosis cutis and calciphylaxis in autoimmune connective tissue diseases","volume":"11","author":"Mormile","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.berh.2026.102162_bib41","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamadermatol.2013.10416","article-title":"Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis","volume":"150","author":"Valenzuela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib42","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102162_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103284","article-title":"Subcutaneous tissue involvement in idiopathic inflammatory myopathies: systematic literature review including three new cases and hypothetical mechanisms","volume":"22","author":"Suzon","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102162_bib44","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/jdv.14932","article-title":"Dermatomyositis panniculitis: a clinicopathological and immunohistochemical study of 18 cases","volume":"32","author":"Santos-Briz","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102162_bib45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2230.1996.tb00151.x","article-title":"Dermatomyositis and flagellate erythema","volume":"21","author":"Jara","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00296-025-05923-2","article-title":"Erythroderma as a presenting feature of dermatomyositis: case-based review","volume":"45","author":"Choubey","year":"2025","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2026.102162_bib47","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1067\/mjd.2000.102648","article-title":"An unusual presentation of dermatomyositis: the type wong variant revisited","volume":"43","author":"Lupton","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib49","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamadermatol.2013.5220","article-title":"Dermatomyositis induced by anti\u2013tumor necrosis factor in a patient with juvenile idiopathic arthritis","volume":"149","author":"Liu","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib50","series-title":"Dermatol","first-page":"689","article-title":"Dermatomyositis","author":"Vleugels","year":"2018"},{"key":"10.1016\/j.berh.2026.102162_bib51","article-title":"The classic Pellagra dermatitis","volume":"13","author":"Madhyastha","year":"2020","journal-title":"BMJ Case Rep CP"},{"key":"10.1016\/j.berh.2026.102162_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2020.107874","article-title":"Clinical and epidemiological descriptions from trichinellosis outbreaks in Bulgaria","volume":"212","author":"Vutova","year":"2020","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.berh.2026.102162_bib53","article-title":"Clinical overview of trichinellosis","year":"2024","journal-title":"Trichinellosis Trichinosis"},{"key":"10.1016\/j.berh.2026.102162_bib54","first-page":"128","article-title":"Knuckle pads versus gottron's papules: making a differential diagnosis","volume":"4","author":"Pereira","year":"2012","journal-title":"J Med Cases"},{"key":"10.1016\/j.berh.2026.102162_bib55","doi-asserted-by":"crossref","unstructured":"Verma I, Dube AH, Kumbhalkar S, et al. A case of palmoplantar keratoderma in the constellation of connective tissue diseases. Cureus n.d.;16:e56531. https:\/\/doi.org\/10.7759\/cureus.56531.","DOI":"10.7759\/cureus.56531"},{"key":"10.1016\/j.berh.2026.102162_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1597282","article-title":"Patients with anti-SAE+ dermatomyositis display refractory and difficult-to-treat skin manifestations: case series from two Italian cohorts and review of literature","volume":"16","author":"Depascale","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102162_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaad.2019.05.105","article-title":"Dermatomyositis: diagnosis and treatment","volume":"82","author":"Waldman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib58","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.berh.2026.102162_bib59","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kex188","article-title":"Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody\u2013positive inflammatory myositis","volume":"56","author":"Abe","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102162_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152858","article-title":"Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: a systematic review and meta-analysis","volume":"75","author":"Gono","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102162_bib61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1743471","article-title":"Association of clinical features and myositis-specific antibodies in idiopathic inflammatory myopathy: a retrospective study from southern China","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102162_bib63","first-page":"741","article-title":"Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study","volume":"21","author":"Castellanos-Gonzalez","year":"2023","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"10.1016\/j.berh.2026.102162_bib64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib65","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22498","article-title":"Cutaneous ulceration in dermatomyositis: association with anti\u2013melanoma differentiation\u2013associated gene 5 antibodies and interstitial lung disease","volume":"67","author":"Narang","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102162_bib66","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S2213-2600(24)00267-4","article-title":"Idiopathic inflammatory myopathies related lung disease in adults","volume":"13","author":"Sehgal","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.berh.2026.102162_bib67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.14801","article-title":"Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis","volume":"176","author":"Ang","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib68","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1111\/ijd.15204","article-title":"Inverse Gottron's papules in patients with dermatomyositis: an underrecognized but important sign for interstitial lung disease","volume":"60","author":"Irie","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/ds.ds_42_19","article-title":"Palmar and lateral digital papules as a distinct feature of fatal anti-melanoma differentiation-associated gene 5 dermatomyositis","volume":"38","author":"Ger","year":"2020","journal-title":"Dermatol Sin"},{"key":"10.1016\/j.berh.2026.102162_bib70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/rheumatology\/keab177","article-title":"Palmar erythema and palmar papules as predictors for dermatomyositis-related acute\/subacute interstitial lung disease: a retrospective study","volume":"61","author":"Lu","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102162_bib71","article-title":"Erythematous auricular papules in the fatal cases of anti-MDA5 antibody-positive interstitial lung disease","volume":"31","author":"Intapiboon","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.berh.2026.102162_bib72","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.17431","article-title":"Antihelix\/Helix violaceous macules in Japanese patients with anti\u2010melanoma differentiation\u2010associated protein 5 (MDA5) antibody\u2010associated dermatomyositis","volume":"180","author":"Okiyama","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib73","article-title":"A novel tool for predicting malignant disease in adult patients with dermatomyositis","author":"Ye","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib74","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.14759","article-title":"Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients","volume":"32","author":"Best","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102162_bib75","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0b013e31819da352","article-title":"Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis","volume":"88","author":"Fardet","year":"2009","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.berh.2026.102162_bib76","first-page":"1601","article-title":"Characteristics of dermatomyositis patients with and without associated malignancy","volume":"19","author":"Lauinger","year":"2021","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"10.1016\/j.berh.2026.102162_bib77","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102162_bib78","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib79","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/1346-8138.15526","article-title":"Clinical features of anti-transcription intermediary factor 1\u03b3 (TIF1\u03b3)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1\u03b3 expression in tumors in the pathogenesis of cancer-associated dermatomyositis","volume":"47","author":"Motegi","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-234111","article-title":"Ovoid palatal patch: a clue to anti-TIF1\u03b3 dermatomyositis","volume":"13","author":"Franciosi","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.berh.2026.102162_bib81","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamadermatol.2016.1429","article-title":"Ovoid palatal patch in dermatomyositis: a novel finding associated with Anti-TIF1\u03b3 (p155) antibodies","volume":"152","author":"Bernet","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib82","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102162_bib83","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102162_bib84","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/rheumatology\/keab518","article-title":"Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash","volume":"61","author":"Ichimura","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102162_bib85","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdcr.2023.05.019","article-title":"Distinctive cutaneous features of dermatomyositis in black adults: a case series","volume":"37","author":"Ezeofor","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.berh.2026.102162_bib86","first-page":"1009","article-title":"Cutaneous manifestations of dermatomyositis in individuals with dark skin: a review of reported cases","volume":"23","author":"Akuffo\u2010Addo","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.berh.2026.102162_bib87","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1111\/jdv.16826","article-title":"The sunburn sign and the suntan sign- two novel findings in Hispanic patients with dermatomyositis","volume":"35","author":"Chavez-Alvarez","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102162_bib88","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/art.24904","article-title":"Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index","volume":"60","author":"Rider","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102162_bib89","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","article-title":"Idiopathic inflammatory myopathies \u2013 a guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd","year":"2017","journal-title":"Clin Med"},{"key":"10.1016\/j.berh.2026.102162_bib90","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4081\/reumatismo.2020.1275","article-title":"The clinical manifestations at the onset of antisynthetase syndrome: a chameleon with multiple faces","volume":"72","author":"Accd","year":"2020","journal-title":"Reumatismo"},{"key":"10.1016\/j.berh.2026.102162_bib91","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaad.2017.10.034","article-title":"Re-examining mechanic's hands as a characteristic skin finding in dermatomyositis","volume":"78","author":"Concha","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib92","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s10067-017-3598-5","article-title":"\u201cHiker's feet\u201d: a novel cutaneous finding in the inflammatory myopathies","volume":"36","author":"Cox","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib93","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/rheumatology\/kead481","article-title":"Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: results from the MYONET registry","volume":"63","author":"Hum","year":"2023","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.berh.2026.102162_bib94","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.berh.2026.102162_bib95","doi-asserted-by":"crossref","unstructured":"Paik JJ, Connolly CM, Wigley F, et al. Systemic sclerosis\u2013associated myopathy in a large single-center cohort: autoantibody profiles, histologic features, and independent risk of death. Arthritis Care Res n.d.;n\/a. https:\/\/doi.org\/10.1002\/acr.25672.","DOI":"10.1002\/acr.25672"},{"key":"10.1016\/j.berh.2026.102162_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004580","article-title":"Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients","volume":"10","author":"Didier","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2026.102162_bib97","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic sclerosis-specific antibodies: novel and classical biomarkers","volume":"64","author":"Cavazzana","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.berh.2026.102162_bib98","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40063","article-title":"Editorial: a new classification of adult autoimmune myositis","volume":"69","author":"Sen\u00e9cal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib99","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102162_bib100","first-page":"118","article-title":"A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies","volume":"31","author":"Cavazzana","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib101","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/mus.28360","article-title":"Clinicopathological features of mixed connective tissue disease-related myositis: a case series","volume":"71","author":"Sakamoto","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.berh.2026.102162_bib102","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1177\/0961203312456751","article-title":"Distinct phenotypes in mixed connective tissue disease: subgroups and survival","volume":"21","author":"Szodoray","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2026.102162_bib103","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10067-021-05717-4","article-title":"Relationship between type of skin lesions and nailfold capillaroscopy pattern in mixed connective tissue disease","volume":"41","author":"Felis-Giemza","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib104","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/0961203320918021","article-title":"Inflammatory myositis in systemic lupus erythematosus","volume":"29","author":"Bitencourt","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2026.102162_bib105","doi-asserted-by":"crossref","unstructured":"L\u00f3pez LA, Vil\u00e1 LM. Dual autoimmunity: a case report of the sequential development of systemic lupus erythematosus in a patient with Anti-MDA5 dermatomyositis. Cureus n.d.;17:e83686. https:\/\/doi.org\/10.7759\/cureus.83686.","DOI":"10.7759\/cureus.83686"},{"key":"10.1016\/j.berh.2026.102162_bib106","doi-asserted-by":"crossref","DOI":"10.5070\/D3274053154","article-title":"Anti-MDA-5 negative, anti-Ku positive clinically amyopathic dermatomyositis","volume":"27","author":"Carrington","year":"2021","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.berh.2026.102162_bib107","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0049-0172(96)80007-2","article-title":"Muscle involvement in rheumatoid arthritis:clinicopathological study of 21 symptomatic cases","volume":"25","author":"Mir\u00f3","year":"1996","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102162_bib108","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2147\/JIR.S503120","article-title":"Clinical features and prognosis of double-positive Anti-MDA5 and Anti-CCP antibodies in dermatomyositis: a retrospective study","volume":"18","author":"Xu","year":"2025","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.berh.2026.102162_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1654576","article-title":"Idiopathic inflammatory myopathy associated with Sj\u00f6gren\u2019s disease: features of a distinct clinical entity","volume":"16","author":"Konen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102162_bib110","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/rheumatology\/keaa257","article-title":"Refining myositis associated with primary Sj\u00f6gren\u2019s syndrome: data from the prospective cohort ASSESS","volume":"60","author":"Felten","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102162_bib111","first-page":"732","article-title":"Other rheumatologic disorders and autoinflammatory diseases","author":"Lenormand","year":"2024","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2026.102162_bib112","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/1346-8138.13344","article-title":"Anti-signal recognition particle antibody-positive polymyositis in a patient with Sj\u00f6gren\u2019s syndrome showing various types of annular erythema: positive correlation between the activities of annular erythema and myositis","volume":"43","author":"Kabuto","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib113","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1111\/ajd.14122","article-title":"CD123 and MxA expression in a case of annular erythema associated with primary Sj\u00f6gren\u2019s syndrome successfully treated with hydroxychloroquine","volume":"64","author":"Matsumura","year":"2023","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib114","doi-asserted-by":"crossref","DOI":"10.1111\/ped.70265","article-title":"Successful treatment with hydroxychloroquine for refractory annular erythema of Sj\u00f6gren\u2019s disease","volume":"67","author":"Hayashi","year":"2025","journal-title":"Pediatr Int"},{"key":"10.1016\/j.berh.2026.102162_bib115","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2026.102162_bib116","first-page":"171","article-title":"Juvenile dermatomyositis without skin lesions","volume":"14","author":"Nilipour","year":"2015","journal-title":"Iran J Neurol"},{"key":"10.1016\/j.berh.2026.102162_bib117","article-title":"An atypical case of dermatomyositis associated with chromophobe renal cell carcinoma","volume":"2016","author":"George","year":"2016","journal-title":"Case Rep"},{"key":"10.1016\/j.berh.2026.102162_bib118","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/1346-8138.17717","article-title":"Persistent exanthema mainly on the trunk with pathologically dermal interstitial mucin as anti-HMGCR myopathy-associated skin rash: case series","volume":"52","author":"Liu","year":"2025","journal-title":"J Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib119","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12865-024-00622-2","article-title":"Atypical skin conditions of the neck and back as a dermal manifestation of anti-HMGCR antibody-positive myopathy","volume":"25","author":"Kurashige","year":"2024","journal-title":"BMC Immunol"},{"key":"10.1016\/j.berh.2026.102162_bib120","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.berh.2026.102162_bib121","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3645","article-title":"Unusual skin involvement in statin-induced Anti-HMGCR immune-mediated necrotizing myopathy","volume":"101","author":"Scard","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.berh.2026.102162_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102691","article-title":"Cutaneous involvement in anti-HMGCR positive necrotizing myopathy","volume":"123","author":"Williams","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.berh.2026.102162_bib123","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s13311-018-0658-8","article-title":"Inclusion body myositis: update on pathogenesis and treatment","volume":"15","author":"Naddaf","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.berh.2026.102162_bib124","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2017.3758","article-title":"Factors associated with clinical remission of skin disease in dermatomyositis","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12016-017-8652-1","article-title":"Cutaneous manifestations of dermatomyositis: a comprehensive review","volume":"53","author":"Mainetti","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.berh.2026.102162_bib126","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/art.1780380819","article-title":"Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet a emissions from a photocopier","volume":"38","author":"Klein","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102162_bib127","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.rdc.2025.09.006","article-title":"Environmental exposures of concern for rheumatologists: ultraviolet radiation","volume":"52","author":"Khosravi-Hafshejani","year":"2026","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.berh.2026.102162_bib128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00128071-200607060-00002","article-title":"Management of cutaneous dermatomyositis","volume":"7","author":"Quain","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib129","doi-asserted-by":"crossref","DOI":"10.5070\/D30Z4408X7","article-title":"Poor compliance with topical corticosteroids for atopic dermatitis despite severe disease","volume":"14","author":"Brown","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.berh.2026.102162_bib130","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archderm.138.9.1231","article-title":"Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus","volume":"138","author":"Pelle","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib131","first-page":"348","article-title":"Use of janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib132","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1093\/rheumatology\/keaf388","article-title":"Improvement of recalcitrant multisystem disease in dermatomyositis with anifrolumab: a case series","volume":"64","author":"Patel","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102162_bib133","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/ced\/llae220","article-title":"Treatment of refractory cutaneous dermatomyositis with oral sirolimus","volume":"49","author":"Dar","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib134","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.berh.2026.102162_bib135","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/rheumatology\/keaf070","article-title":"Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study","volume":"64","author":"Charles-Schoeman","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102162_bib136","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/ced.13607","article-title":"Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis","volume":"43","author":"Galimberti","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib137","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3988\/jcn.2020.16.1.160","article-title":"Refractory digital ulcers treated by botulinum toxin and endothelin Receptor-1 antagonist in Anti-MDA5-Antibody-Positive dermatomyositis","volume":"16","author":"Min","year":"2020","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.berh.2026.102162_bib138","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2010.08.039","article-title":"Calcinosis cutis: part II. Treatment options","volume":"65","author":"Reiter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib139","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the janus-kinase inhibitor tofacitinib \u2013 a report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.berh.2026.102162_bib140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2019.07.006","article-title":"Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature","volume":"82","author":"Traineau","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib141","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jdcr.2023.09.043","article-title":"Efficacy of topical ruxolitinib for cutaneous dermatomyositis","volume":"45","author":"Lanis","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.berh.2026.102162_bib142","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000548207","article-title":"Successful treatment of refractory dermatomyositis with deucravacitinib (Sotyktu): a case report","volume":"17","author":"Lapa","year":"2025","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib143","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jdcr.2025.01.047","article-title":"Successful treatment of recalcitrant amyopathic dermatomyositis with deucravacitinib in addition to intravenous immunoglobulin","volume":"62","author":"McNamara","year":"2025","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.berh.2026.102162_bib144","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdcr.2025.10.010","article-title":"Novel use of deucravacitinib for treatment of recalcitrant TIF1-gamma dermatomyositis","volume":"66","author":"Burli","year":"2025","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.berh.2026.102162_bib145","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jid.2025.10.563","article-title":"364 efficacy and safety of brepocitinib in patients with active dermatomyositis: results from a randomized, double-blind, multicenter, placebo-controlled, phase III (VALOR) trial","volume":"145","author":"Paik","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib146","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf662","article-title":"Real-world experience of anifrolumab in 30 patients with refractory DM: a multicentre\u2013multidisciplinary retrospective study","volume":"65","author":"Retuerto-Guerrero","year":"2026","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102162_bib147","article-title":"Anifrolumab in refractory dermatomyositis and antisynthetase syndrome","volume":"2025","author":"Soares","year":"2025","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib148","first-page":"1635","article-title":"A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to determine the effectiveness of the type I interferon receptor antibody, anifrolumab, in SYstemic sclerosis: DAISY study design and rationale","volume":"42","author":"Khanna","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2026.102162_bib149","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, safety, and target engagement of dazukibart, an IFN\u03b2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2026.102162_bib150","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jamadermatol.2022.3917","article-title":"Apremilast in recalcitrant cutaneous dermatomyositis: a nonrandomized controlled trial","volume":"158","author":"Bitar","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib151","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in dermatomyositis patients with refractory skin","volume":"142","author":"Werth","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.berh.2026.102162_bib152","article-title":"Experience on the use of obinutuzumab off label in patients with refractory idiopathic inflammatory myopathy","author":"Ilic","year":"2024","journal-title":"ACR Meet Abstr"},{"key":"10.1016\/j.berh.2026.102162_bib153","article-title":"Effect of efgartigimod PH20 SC on total improvement score, its core set measures, and patient\/clinician impressions of change: results from the phase 2 ALKIVIA study of adults with active idiopathic inflammatory myopathy","author":"Aggarwal","year":"2025","journal-title":"ACR Meet Abstr"},{"key":"10.1016\/j.berh.2026.102162_bib154","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease \u2014 a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102162_bib155","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol Ther J Am Soc Gene Ther"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:12:07Z","timestamp":1793607127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":155,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1521694226000471"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102162","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous manifestations in myositis syndromes","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102162"}}